StreetAlpha.app
Home › Stocks › EYPT

EyePoint, Inc. (EYPT)

Healthcare
$0.30
▼ −0.16%
LAST CLOSE · NOV 17

EyePoint develops DURAVYU, an investigational sustained release eye treatment for serious retinal diseases. It last closed at $0.30 on Nov 17, down 0.16% on the day. The average 12-month price target from 3 analysts is $3.33 (+1000.5% from the last close), with a high of $5.00 and a low of $1.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell).

AI Auto Pilots
Is EYPT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.6M
−93.9% vs a year ago
Net income
−$342.5M
−13281.2% margin
EPS (diluted)
−$3.97
Free cash flow
−$299.1M
−11599.4% margin
Valuation
Market cap
$34.5M
113.8M shares
P/E
–
No P/E while losing money
Price to sales
13.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$83.2M
At Sep 30
Shareholder equity
$108.5M
Shares outstanding
113.8M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $36.9M$36.9MFY2021FY2022: $41.4M$41.4MFY2022FY2023: $46.0M$46.0MFY2023FY2024: $43.3M$43.3MFY2024FY2025: $31.4M$31.4MFY2025

From EYPT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
3firms
1 Buy2 Hold0 Sell
Each firm's latest rating on EYPT in the past 90 days
Average 12-month target
$3.33
▲ 1000.5% upside

Based on 3 analysts who set a price target on EYPT in the past 90 days. The average target is $3.33, with a high of $5.00 and a low of $1.00, compared with the last close of $0.30.

$-1$5$10$16PAST 26 TRADING DAYS12-MONTH TARGETSHIGH $5AVG $3.33LOW $1Jun 15LAST CLOSE+12 MO$-1$5$10$16PAST 26 DAYSTARGETSHIGH $5AVG $3.33LOW $1Jun 15LAST CLOSE+12 MO
Highest target$5.00
Average target$3.33
Lowest target$1.00
Latest rating changes
StifelTarget lowered
Nov 13Buy$40 → $5
RBC CapitalTarget lowered
Oct 20Hold$5 → $1
TD CowenDowngrade
Sep 2Hold$4
CitigroupMaintained
Aug 18Buy$17
RBC CapitalDowngrade
Aug 18Hold$5
DateFirmActionRatingPrice target
Nov 13StifelTarget loweredBuy$40 → $5
Oct 20RBC CapitalTarget loweredHold$5 → $1
Sep 2TD CowenDowngradeHold$4
Aug 18CitigroupMaintainedBuy$17
Aug 18RBC CapitalDowngradeHold$5
Loading…

Technical Analysis

EYPT · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 21% below its 20 day and 612% below its 50 day average. It is 3234% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 18), oversold. The nearest support is the Pivot at $0.30, and the nearest resistance the Pivot R1 at $0.32.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 42.2%/day
Key levels
$19.1152 week high+6270.0%
$10.10200 day average+3266.7%
$6.38100 day average+2026.7%
$2.1650 day average+620.0%
$0.41Swing high (Nov 10)+36.7%
$0.3720 day average+23.3%
$0.32Pivot R1+6.7%
$0.30Pivot+0.0%
$0.30Last close
$0.29Pivot S1−3.3%
$0.2852 week low−6.7%
Indicators
RSI (14)18.15Oversold below 30Oversold
MACD-0.58Above its signal lineBullish
Stochastic9.4Near the bottom of its rangeOversold
ADX (14)64.0Strong downtrend
Williams %R-86.4Oversold below −80, overbought above −20Oversold
CCI (20)-159.7Oversold below −100, overbought above 100Oversold
Rate of change−24.3%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 42.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EYPT

What happened before

See how EYPT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow EYPT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EYPT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in EYPT in the last 90 days.

Loading…

See today’s whale options flow across the market →

EYPT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲112 buying vs 97 selling
  • ▲Held by funds +2.7 pts
  • ●Funds holding +0
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1901900.0%
In funds' top 1017−85.7%
Held by funds84.4%81.6%+2.7 pts
New / increased44 / 6825 / 65+24.4%
Reduced / sold out54 / 4360 / 24+15.5%
Put/call ratio0.983.17−69.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EYPT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EYPT is in one of them and how their past EYPT trades turned out.

EYPT in the AI portfolios
Loading…

EYPT News & Analysis

All StreetAlpha news →
EYPT in the news

About EyePoint

EyePoint is a biopharmaceutical company based in Watertown, Massachusetts, that develops treatments for serious retinal diseases of the eye. Its lead candidate, DURAVYU, combines the drug vorolanib with the company's Durasert E drug delivery technology, which is designed to release medicine steadily inside the eye over a long period. The company is testing DURAVYU for wet AMD and diabetic macular edema, and the treatment has not been approved by the FDA. Its intended patients are people with these conditions, and the eye doctors who would treat them.

Headquarters
Watertown, MA